On January $1,2023,$ Pulaski, Incorporated, acquired a $60$ percent interest in the common stock of Sheridan, Incorporated, for $$362,400.$ Sheridan's book value on that date consisted of common stock of $$100,000$ and retained earnings of $$214,200.$ Also, the acquisition$-$date fair value of the $40$ percent noncontrolling interest was $$241,600.$ The subsidiary held patents $($with a $10-$year remaining life$)$ that were undervalued within the company's accounting records by $$82,600$ and also had unpatented technology $(15-$year estimated remaining life$)$ undervalued by $$57,900.$ Any remaining excess acquisition$-$date fair value was assigned to an indefinite$-$lived trade name. Since acquisition, Pulaski has applied the equity method to its Investment in Sheridan account. At year$-$end, there are no intra$-$entity payables or receivables.

Intra$-$entity inventory sales between the two companies have been made as follows:

$\backslash$table$[[,$Cost to$,$Transfer Price,$\backslash$table$[[$Ending Balance$],[($at transfer$]]],[$Year$,$Pulaski,to Sheridan,price$)],[2023,$$$132,000,$$$165,000,$$$55,000$